Tag: Aids

First approved by the FDA in 2007, Isentress was the pioneering integrase inhibitor developed to treat HIV-1 infection. The medication, also known by its generic name raltegravir, is a crucial part of combination antiretroviral therapy (ART) and is used for both treatment-naive and treatment-experienced patients.

Antiretroviral therapy (ART) has dramatically changed HIV from a fatal diagnosis to a manageable chronic condition, largely due to the development of **ARV**, or antiretroviral drugs. These medications are the backbone of modern HIV treatment and prevention strategies, giving the immune system a chance to recover by controlling viral replication.

Freddie Mercury was officially diagnosed with AIDS in 1987, the same year the first antiretroviral drug, AZT, was approved by the FDA [1.5.2, 1.3.6]. The question of **did Freddie Mercury take AZT** is complex, reflecting the harsh realities of early HIV treatment.

Over 90% of people who take antiretroviral therapy (ART) as prescribed achieve an undetectable viral load within 12 months, allowing their immune system to recover and live long, healthy lives. It is a persistent and dangerous myth that ARV drugs weaken the immune system, but the opposite is true. This article will separate fact from fiction and explain the critical role of ARVs in restoring and preserving immune function in people living with HIV.

Over 80% of adults worldwide are seropositive for cytomegalovirus (CMV), a common virus that poses little threat to healthy individuals. However, for those with weakened immune systems, CMV can lead to severe complications, making medication like **Cytoniche 450 mg** a critical treatment option. This powerful antiviral helps manage and prevent serious CMV infections in vulnerable patient populations.

Approved by the FDA in 1987 as the first antiretroviral drug, Retrovir (zidovudine or AZT) revolutionized the treatment of HIV/AIDS. Its primary use today, in combination with other medications, is to manage HIV infection and prevent its transmission from mother to child.

Approved by the FDA in 1987, azidothymidine (AZT) was the very first antiretroviral medication for treating HIV. To understand how does AZT work, one must first grasp its role as a nucleoside analog that disrupts the virus's replication cycle by targeting a key viral enzyme.

As the first approved HIV fusion inhibitor, Fuzeon (enfuvirtide) marked a major step forward in addressing the unmet needs of patients with limited treatment options. **What does Fuzeon treat?** It is a critical medication for treating multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients who have experienced treatment failure with other antiretroviral therapies.

First approved by the FDA in 2001, valganciclovir is a highly effective antiviral drug that serves as a prodrug for ganciclovir and is used to treat and prevent cytomegalovirus (CMV) infections. This oral medication offers a convenient alternative to intravenous ganciclovir for controlling CMV-related illnesses, especially in immunocompromised patients.

Approved by the FDA in 2003, Fuzeon was the first medication of its kind to target the fusion step of the HIV lifecycle. This powerful antiretroviral helps answer the question, **what does Fuzeon do?**, by explaining its unique action against the virus in treatment-experienced patients.